Masakazu Toi 研究室
主宰者:Masakazu Toi
京都大学
AI 要約(直近 5 年の研究成果)
Masakazu Toi研究室は、乳がんの診断と治療を改善するための臨床研究を中心に行っています。特に、HER2陽性乳がんやホルモン受容体陽性乳がんといった異なるタイプの乳がんに対して、新しい治療薬の効果を検証する臨床試験に取り組んでいます。化学療法の前に行う治療法の効果判定、手術の方法改善、そして患者さんの治療後の生存率向上といった、実際の患者さんの診療に直結した課題に向き合っています。
研究の特徴として、単一施設の経験だけでなく、全国規模のデータベースを活用した大規模な分析を行っている点が挙げられます。遺伝子検査を含む生物学的特性の詳細な解析を通じて、どの患者さんがどの治療に反応しやすいかを予測することを目指しています。また、医療画像の解析やAI技術の活用、手術時の最新機器の導入効果の検証など、多角的なアプローチで乳がん医療を進化させようとしています。
さらに、COVID-19パンデミックが乳がん診断に与えた影響を調査するなど、社会的背景に基づく医療課題にも注目しています。このように、基礎的な分子メカニズムから臨床実践まで幅広いスケールで、患者さんの予後改善に貢献する研究を展開している研究室です。
※ AI(Claude)が、公開されている論文要旨から研究の問い・手法・主要な発見を事実情報として抽出・再構成して自動生成しています。誤りを含む可能性があるため、正確性は研究室公式情報でご確認ください。
外部リンク
関連研究室(8 件)
- 生化学・分子生物学・遺伝学Hideyoshi Harashima 研究室北海道大学論文 74 件·共通: DNA, 生物学, 分子・細胞, 分子 +8
- 神経科学Yasuo Mori 研究室九州大学論文 68 件·共通: 情報工学, OS, 計算機科学, システム +8
- 生化学・分子生物学・遺伝学Hideyuki Okano 研究室慶應義塾大学論文 100 件·共通: RNA, 生物学, 分子・細胞, 分子 +5
- 生化学・分子生物学・遺伝学Takashi Ito 研究室九州大学論文 56 件·共通: DNA, 生物学, 分子・細胞, 分子 +5
- 生化学・分子生物学・遺伝学Masahira Hattori 研究室早稲田大学論文 42 件·共通: DNA, 生物学, 分子・細胞, 分子 +5
- 生化学・分子生物学・遺伝学Kohei Miyazono 研究室東京大学論文 30 件·共通: DNA, 生物学, 分子・細胞, 分子 +5
- 生化学・分子生物学・遺伝学Saneyuki Kawabata 研究室東京大学論文 24 件·共通: 生物学, 分子・細胞, 分子, CRISPR +5
- 生化学・分子生物学・遺伝学Yukinori Okada 研究室東京大学論文 101 件·共通: RNA, 生物学, 分子・細胞, 分子 +4
研究成果(100 件)
- Correction: Honda et al. Visual Evaluation of Ultrafast MRI in the Assessment of Residual Breast Cancer After Neoadjuvant Systemic Therapy: A Preliminary Study Association with Subtype. Tomography 2022, 8, 1522–1533DOI: https://doi.org/10.3390/tomography12010006
- Ethnic and geographic diversity of BRCA1/2 variants: a narrative review of pathogenic variants and VUSDOI: https://doi.org/10.21037/bc-25-51
- Controlling Nutritional Status (CONUT) score as a key predictor of disability following conservative treatment of osteoporotic vertebral fracturesDOI: https://doi.org/10.1007/s00198-025-07826-1
- Dynamic changes in serum HER2-peptide-specific autoantibodies predict response to neoadjuvant therapy in HER2-positive breast cancerDOI: https://doi.org/10.1186/s13058-026-02259-y
- 201P Abemaciclib (abema) combined with adjuvant endocrine therapy (ET) in patients from monarchE in Asia with high-risk early breast cancer (EBC)DOI: https://doi.org/10.1016/j.esmoop.2025.104755
- Reply to: Germline and Somatic <i>BRCA1/2</i> Mutations in Breast Cancer Treatment StrategiesDOI: https://doi.org/10.1200/po-25-00588
- [2025] 脊椎手術後の手術部位感染予防:ケアバンドルの効果Prevention of Surgical Site Infection after Spine Operation with Care BundleDOI: https://doi.org/10.1089/sur.2025.007
- Abstract P2-03-16: Prevalence of PIK3CA/AKT1/PTEN and other genomic alterations in primary and recurrent tumor tissue: exploratory analysis from the Phase 3 CAPItello-291 clinical trialDOI: https://doi.org/10.1158/1557-3265.sabcs24-p2-03-16
- 282P Evaluation of the diagnostic performance and utility of artificial Intelligence-based computer-aided diagnosis in Japanese women with early-stage breast cancerDOI: https://doi.org/10.1016/j.esmoop.2025.104837
- Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast CancerDOI: https://doi.org/10.1056/nejmoa2508668
続きを表示(残り 90 件)閉じる
- Survival of patients with squamous cell carcinoma of the breast compared with invasive ductal carcinoma by biological subtype: A matched analysis of the Japanese national clinical database-breast cancer registryDOI: https://doi.org/10.1016/j.breast.2025.104567
- [2025] カピバセルチブ+フルベストラント:アロマターゼ阻害剤治療中/後に再発・増悪したHR陽性/HER2陰性進行乳癌患者における第3相CAPItello-291試験のPTEN欠損に関する探索的解析Abstract P2-03-19: Capivasertib-fulvestrant for patients w/ HR-pos/HER2-negative advanced breast cancer who had relapsed or progressed during or after aromatase inhibitor treatment: exploratory analysis of PTEN deficiency by IHC from phase III CAPItello-291 trialDOI: https://doi.org/10.1158/1557-3265.sabcs24-p2-03-19
- Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2–positive (HER2+) advanced/metastatic breast cancer (a/mBC): Interim results from DESTINY-Breast09.DOI: https://doi.org/10.1200/jco.2025.43.17_suppl.lba1008
- Detection capability of the Medical Imaging Projection System for sentinel lymph node biopsy in patients with breast cancer with and without neoadjuvant chemotherapy: a retrospective studyDOI: https://doi.org/10.1007/s12282-025-01712-8
- Abstract P4-07-09: Does energy device improve operative procedure and postoperative management of total mastectomy with axillary lymph node dissection?DOI: https://doi.org/10.1158/1557-3265.sabcs24-p4-07-09
- Dynamic Interspinous Process Distance and Adjacent Vertebral Fracture After Balloon Kyphoplasty: Preliminary Evidence From a Single-Center CohortDOI: https://doi.org/10.7759/cureus.93578
- [2025] ネオアジュバント内分泌療法後のPAM50サブタイプ変化:ER+HER2-手術可能乳癌に対するホルモン療法+パルボシクリブ対ホルモン療法+プラセボの第3相二重盲検ランダム化ネオアジュバント試験Abstract P5-04-28: Subtype by PAM50 changes after Neoadjuvant Endocrine therapy, from A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy plus Palbociclib versus Hormonal Therapy plus Placebo in ER+HER2- Operable Breast CancerDOI: https://doi.org/10.1158/1557-3265.sabcs24-p5-04-28
- A novel percutaneous sacral endplate penetrating screw technique: enhanced fixation strength with the M-probe: surgical techniqueDOI: https://doi.org/10.21037/jss-25-15
- Abemaciclib Plus Fulvestrant in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Final Overall Survival Results From MONARCH 2DOI: https://doi.org/10.1200/oa-25-00052
- Adjuvant S-1 plus endocrine therapy for ER-positive, HER2-negative, primary breast cancer: post-POTENT trial prognostic surveyDOI: https://doi.org/10.1038/s41523-025-00832-w
- Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancerDOI: https://doi.org/10.1530/erc-24-0353
- Impact of the COVID-19 pandemic on breast cancer diagnosis and treatment trends in JapanDOI: https://doi.org/10.1007/s12282-025-01718-2
- Abstract 1636: Novel CDK12/13 inhibitor CTX-439 downregulates MCL1 via transcriptional mRNA read-through and synergistically acts with BCL-XL inhibitors for cancer therapyDOI: https://doi.org/10.1158/1538-7445.am2025-1636
- DOI: https://doi.org/10.12936/tenrikiyo.28-007
- Locoregional indicators of systemic spread in breast cancer: insights from standard-of-care imaging and ¹⁸F-FDG PET/CTDOI: https://doi.org/10.1007/s12149-025-02124-6
- DOI: https://doi.org/10.1200/po-24-00742
- DOI: https://doi.org/10.3390/jcm14082769
- DOI: https://doi.org/10.1016/j.annonc.2025.03.010
- DOI: https://doi.org/10.1200/jco-24-01673
- Subcutaneous/cutaneous uptake in the cancer-affected breast on 18F-FDG PET/CT: association with post-surgical prognosis in breast cancer patientsDOI: https://doi.org/10.1007/s12149-025-02106-8
- DOI: https://doi.org/10.1016/j.bonr.2024.101762
- DOI: https://doi.org/10.21037/actr-24-114
- DOI: https://doi.org/10.1080/14796694.2024.2390791
- DOI: https://doi.org/10.1016/j.spinee.2024.08.009
- DOI: https://doi.org/10.1016/j.ebiom.2024.105271
- DOI: https://doi.org/10.1007/s10147-024-02604-1
- DOI: https://doi.org/10.2196/58977
- DOI: https://doi.org/10.2463/jjmrm.2024-1811
- DOI: https://doi.org/10.58530/2023/2730
- DOI: https://doi.org/10.31616/asj.2023.0443
- DOI: https://doi.org/10.1016/j.tranon.2024.102060
- DOI: https://doi.org/10.1136/spcare-2024-005024
- DOI: https://doi.org/10.1007/s12282-024-01604-3
- DOI: https://doi.org/10.1016/j.esmoop.2024.103466
- DOI: https://doi.org/10.1007/s10549-024-07333-7
- DOI: https://doi.org/10.1158/1538-7445.sabcs23-gs01-12
- DOI: https://doi.org/10.1158/1538-7445.sabcs23-ps02-02
- DOI: https://doi.org/10.1158/1538-7445.sabcs23-po4-25-01
- DOI: https://doi.org/10.1158/1538-7445.sabcs23-po4-02-04
- DOI: https://doi.org/10.1016/j.esmoop.2024.103205
- [2024] Abstract 106: Selective elimination of CD169+ macrophages in lymph nodes invaded by breast cancersDOI: https://doi.org/10.1158/1538-7445.am2024-106
- DOI: https://doi.org/10.1016/j.jjcc.2024.03.005
- DOI: https://doi.org/10.1158/1538-7445.am2024-5266
- DOI: https://doi.org/10.1158/1538-7445.am2024-121
- DOI: https://doi.org/10.1007/s12282-024-01550-0
- DOI: https://doi.org/10.1016/s1470-2045(23)00615-0
- DOI: https://doi.org/10.1186/s12905-024-03003-4
- DOI: https://doi.org/10.1200/jco.23.01214
- DOI: https://doi.org/10.1007/s13691-023-00646-2
- DOI: https://doi.org/10.1038/s41416-023-02527-0
- DOI: https://doi.org/10.1007/s12282-023-01532-8
- [2024] Construction of a prognostic survival model with tumor immune-related genes for breast cancerDOI: https://doi.org/10.21037/tcr-24-2137
- DOI: https://doi.org/10.1038/s41467-024-53706-3
- DOI: https://doi.org/10.1158/2326-6074.tumimm24-a019
- DOI: https://doi.org/10.1007/s12282-024-01640-z
- DOI: https://doi.org/10.1111/cas.16339
- DOI: https://doi.org/10.1158/1538-7445.sabcs23-ps17-03
- DOI: https://doi.org/10.1007/s12282-024-01545-x
- DOI: https://doi.org/10.1016/j.esmoop.2024.103697
- DOI: https://doi.org/10.1016/j.annonc.2024.08.184
- DOI: https://doi.org/10.1016/s1470-2045(24)00373-5
- DOI: https://doi.org/10.58530/2022/0148
- DOI: https://doi.org/10.1016/j.annonc.2023.08.017
- DOI: https://doi.org/10.58530/2022/0550
- DOI: https://doi.org/10.1111/cas.15935
- DOI: https://doi.org/10.1002/cam4.6390
- DOI: https://doi.org/10.1038/s41586-023-06333-9
- DOI: https://doi.org/10.1007/s10549-023-07030-x
- DOI: https://doi.org/10.1007/s10549-023-07022-x
- DOI: https://doi.org/10.1007/s00330-023-09730-w
- DOI: https://doi.org/10.1007/s12149-023-01846-9
- DOI: https://doi.org/10.1007/s00595-023-02786-7
- DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.1015
- DOI: https://doi.org/10.1055/s-0043-1769139
- DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.e13031
- DOI: https://doi.org/10.1056/nejmoa2214131
- DOI: https://doi.org/10.1007/s10549-023-07163-z
- DOI: https://doi.org/10.1016/j.annonc.2023.11.016
- DOI: https://doi.org/10.1016/j.breast.2023.103623
- DOI: https://doi.org/10.1007/s12282-023-01526-6
- [2023] Periportal hepatocyte proliferation at midgestation governs maternal glucose homeostasis in miceDOI: https://doi.org/10.1038/s42003-023-05614-3
- DOI: https://doi.org/10.1038/s42003-023-05433-6
- DOI: https://doi.org/10.1007/s12282-023-01517-7
- DOI: https://doi.org/10.1093/oncolo/oyad301
- DOI: https://doi.org/10.1016/j.ejca.2023.113420
- DOI: https://doi.org/10.1158/1078-0432.ccr-22-3573
- DOI: https://doi.org/10.1089/jwh.2023.0663
- DOI: https://doi.org/10.1186/s12885-023-11291-6
- DOI: https://doi.org/10.1007/s10549-023-07099-4
科研費(0 件)
まだデータがありません(KAKEN 取り込み後に表示)。
所属学会・役職(0 件)
まだデータがありません(学会データ連携後に表示)。